• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Technologies
    • Balloons
    • Brain-computer interfaces
    • Cardiac Implants
    • Catheters
    • Endoscopes
    • Heart valves
    • Pulsed Field Ablation
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Molding
      • Injection Molding
      • Insert molding
      • Mold Components
    • Tools
  • Materials
    • Advanced Materials
    • Metals
    • Nitinol
    • Plastics
    • Silicone
  • Business
    • Distribution Agreements
    • Legal News
    • Mergers & Acquisitions
    • Partnerships
    • Personnel Moves
  • Regulatory
    • 510(k)
    • CE Mark
    • FDA Breakthrough Designation
    • ISO Certification
    • Pre-Market Approval (PMA)
    • Recalls
  • Suppliers
  • About Us

Boston Scientific shares positive drug-coated balloon data

October 27, 2023 By Sean Whooley

Boston Scientific Agent drug-coated balloon DCB
The Agent drug-coated balloon. [Image from Boston Scientific]
Boston Scientific [WtwhTicker symbol=”BSX”](NYSE: BSX)[/WtwhTicker] announced positive data from a trial of its Agent drug-coated balloon (DCB).

The Marlborough, Massachusetts-based company presented its results at the Transcatheter Cardiovascular Therapeutics (TCT) meeting. Data demonstrated statistical superiority for Agent compared to uncoated balloon angioplasty.

AGENT IDE evaluated the safety and effectiveness of using a DCB to treat coronary in-stent restenosis (ISR). The paclitaxel-coated balloon catheter offers an alternative to treatments like stent layering or radiation. It’s designed to re-open vessels and transfer the therapeutic drug to the vessel wall, helping to prevent ISR reoccurrence.

The Agent DCB has FDA breakthrough device designation.

Boston Scientific set a primary endpoint of target lesion failure at 12 months. Agent DCB topped balloon angioplasty with 17.9% target lesion failure compared to 28.7%.

Other key findings include zero definite/probable cases of clotting within the stent (stent thrombosis). That compared to 3.9% stent thrombosis with uncoated balloon angioplasty. Additionally, Boston Scientific reported a 51% risk reduction in toll-like receptors (TLR, 12.4% vs. 24%). The study saw a 49% risk reduction in target vessel-myocardial infarction (TV-MI, 6.4% vs. 12.3%).

“On behalf of our diverse steering committee, study investigators/coordinators, and especially on behalf of all the patients who participated in this trial, it is so gratifying to see these results which will hopefully facilitate the first approval of a dedicated coronary drug-coated balloon in the United States – fulfilling a huge unmet need for patients,” said trial chair Dr. Ajay Kirtane, director of the Columbia Interventional Cardiovascular Care program and professor of medicine at the Columbia University Irving Medical Center.

Filed Under: Balloons, Catheters Tagged With: Boston Scientific

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“mte
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest trends and developments in medical tubing and extrusion.
MDO ad

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World
Drug Delivery Business News

Medical Tubing + Extrusion

Subscribe to our E-Newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS